Evolv Technologies director Michael Ellenbogen sold 80,745 shares of Class A Common Stock on July 15, 2026, for approximately $480,000 at $5.94 per share. The transaction was structured as an exercise of 80,745 stock options at a strike price of $0.24 per share followed by an immediate open-market sale, capturing the spread on vested equity awards through a pre-arranged Rule 10b5-1 trading plan established on June 12, 2025. Following the sale, Ellenbogen's total beneficial ownership remains at about 2.2 million shares, including roughly 2.1 million shares held directly and 151,000 shares held indirectly through the Family Horizon Trust, along with 897,014 derivative securities. Evolv Technologies reported trailing twelve-month revenue of $160.2 million and a net loss of $36.5 million, with a total market capitalization of $1.0 billion as of the July 16, 2026 market close. First-quarter revenue rose 45% to $46.3 million, and recurring revenue reached $127.3 million, up 20%, prompting management to lift full-year guidance to between $175 million and $180 million.
Evolv Technologies Holdings IncDirector sold shares via 10b5-1 plan, but the sale is pre-arranged and not necessarily indicative of negative outlook; company fundamentals remain strong with raised guidance.